Voxelotor for the treatment of sickle cell disease

References

• Ataga KI, Gordeuk VR, Agodoa I, et al., Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis. PLoS One. 15(4):e0229959. 2020.
   PubMed Web of Science ®Google Scholar
• CDC Data & Statistics on Sickle Cell Disease | CDC. Centers for Disease Control and Prevention. [ Published 2016 Aug 31; cited 2019 Jul 28]. Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html
   Google Scholar
• Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484.
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. 433021. 2013;128(2):110–116.
   Google Scholar
• Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128(10):1436–1438.
   PubMed Web of Science ®Google Scholar
• Osunkwo I (ify), Andemariam B, Inusa BP, et al. Impact of sickle cell disease symptoms on patients’ daily lives: interim results from the international sickle cell world assessment survey (SWAY). Blood. 2019;134(Supplement_1): 2297-2297.
   Google Scholar
• Knisely MR, Pugh N, Kroner B, et al. Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: report from the sickle cell disease implementation consortium. Am J Hematol. 2020;95(9):1066–1074.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Connes P. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: the effect of hydroxyurea, fetal hemoglobin, and α-thalassemia. Eur J Haematol. 2018;101(6):798–803.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Smith WR, Stark CW, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018 Nov 8;379(19):1880.
   PubMedGoogle Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429–439.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011;153(1):92–104.
   PubMed Web of Science ®Google Scholar
• Brousseau DC, Scott JP, Badaki-Makun O, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015;126(14):1651–1657.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625–635.
   PubMed Web of Science ®Google Scholar
• Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175(1):141–153.
   PubMed Web of Science ®Google Scholar
• Wireko FC, Kellogg GE, Abraham DJ. Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors. J Med Chem. 1991 Feb;34(2):758–767.
   PubMed Web of Science ®Google Scholar
• Abdulmalik O, Safo MK, Chen Q, et al. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552–561.
   PubMed Web of Science ®Google Scholar
• Patel M, Cabrales P, Dufu K, et al. GTx011, an anti-sickling compound, improves SS blood rheology by reduction of hbs polymerization via allosteric modulation of O2 affinity. Blood. 2014;124(21): 1370-1370. DOI:10.1182/blood.V124.21.1370.1370.
   Web of Science ®Google Scholar
• Dufu K, Patel M, Oksenberg D, et al. GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clin Hemorheol Microcirc. 2018;70(1):95–105.
   PubMed Web of Science ®Google Scholar
• Dufu K, Oksenberg D. GBT440 reverses sickling of sickled red blood cells under hypoxic conditions in vitro. Hematol Rep. 2018 May 14;10(2):7419.
   PubMed Web of Science ®Google Scholar
• Howard J, Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019 Apr 25;133(17):1865–1875.
   PubMed Web of Science ®Google Scholar
• OXBRYTA TM (voxelotor) tablets for oral use [package insert] Global Blood Therapeutics, Inc. 2019 Nov.
   Google Scholar
• Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017 Mar 9;8(3):321–326.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019 Aug 8;381(6):509–519.
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga KI, Brown RC, et al. Efficacy and safety of voxelotor in adolescents and adults with sickle cell disease: HOPE trial 72-week analysis. Blood. 2020;136(Supplement 1): 19-19. DOI:10.1182/blood-2020-140553.
   Google Scholar
• Vichinsky E, Gordeuk VR, Telfer P, et al. Higher hemoglobin levels achieved with voxelotor are associated with lower vaso-occlusive crisis incidence: 72-week analysis from the HOPE study. Blood. 2020;136(Supplement 1):31–32.
   Google Scholar
• Blyden G, Bridges KR, Bronte L. Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access. Am J Hematol. 2018.
   PubMedGoogle Scholar
• Shet AS, Mendelsohn L, Harper J, et al. Voxelotor treatment of a patient with sickle cell disease and very severe anemia. Am J Hematol. 2019 Apr;94(4):E88–E90.
   PubMed Web of Science ®Google Scholar
• Telfer P, Agodoa I, Fox KM, et al. Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease. Hematol Rep. 2018 May 14;10(2):7643.
   PubMed Web of Science ®Google Scholar
• Betancourt JL, You S, Minniti C, et al. Real world clinical experience with oxbryta therapy in individuals with sickle cell disease. In Paper presented at 62nd ASH Annual Meeting and Exposition; 2020 Dec 6; Virtual Meeting.
   Google Scholar
• Ershler WB, Holbrook ME. Sickle cell anemia and COVID-19: use of voxelotor to avoid transfusion. Transfusion. 2020 Dec;60(12):3066-3067. doi:10.1111/trf.16068. Epub 2020 Sep 24.
   Web of Science ®Google Scholar
• DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–1588.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Inati A, Brown C, et al. Initial results from a cohort in a phase 2A study (GBT440-007) evaluating adolescents with sickle cell disease treated with multiple doses of voxelotor, a sickle hemoglobin polymerization inhibitor [Conference Abstract]. Pediatr Blood Cancer. 2018;65:S91–S92.
   Web of Science ®Google Scholar
• Brown C, Hoppe C, Inati A, et al. Efficacy and safety of 1500 mg voxelotor in a phase 2a study (GBT440-007) in adolescents with sickle cell disease. Blood. 2018;132(Supplement 1): 509-509. DOI:10.1182/blood-2018-99-117510.
   Google Scholar
• Nebor D, Kanne C, Sheehan V, et al. Rheological impact of GBT1118 cessation in a sickle mouse model. In Paper presented at 62nd ASH Annual Meeting and Exposition; 2020 Dec 6; Virtual Meeting.
   Google Scholar
• Savedra ME, Szuberski JL, Porter TR, et al. Effects of Voxelotor (GBT440) Therapy on Laboratory Testing of Sickle Cell Patients. Blood. 2019;134(Supplement_1): 1011-1011. DOI:10.1182/blood-2019-131125.
   Google Scholar
• Crizanlizumab Voxelotor and L-glutamine for sickle cell disease: effectiveness and value: evidence report. Inst Clin Econ Rev (ICER). 2020 Mar;12; 23–27.
   Google Scholar
• Kalpatthi R, Novelli EM. Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. Hematol Am Soc Hematol Educ Program. 2018Nov30;2018(1):482–492.
   PubMedGoogle Scholar
• Choi S, O’Neil SH, Joshi AA, et al. Anemia predicts lower white matter volume and cognitive performance in sickle and non-sickle cell anemia syndrome. Am J Hematol. 2019 Oct;94(10):1055–1065.
   PubMed Web of Science ®Google Scholar
• Ameringer S, Elswick RK, Smith W. Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs. 2014;31(1):6–17.
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Telfer P, Inati A, et al. Incidence of vaso-occlusive crisis does not increase with achieving higher hemoglobin levels on voxelotor treatment or after discontinuation: analyses of the HOPE study. Blood. 2019;134(Supplement_1): 2313-2313. DOI:10.1182/blood-2019-129026.
   Google Scholar